Study: NCT05658692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: protective ventilation
Description: Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prone position ventilation
Description: patients with moderate to severe ARDS who don't have contraindications were given prone ventilation for over 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucocorticoid therapy
Description: Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.~Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restrictive fluid resuscitation
Description: 1. without other organ dysfunction patients: Minimize fluid was given;~2. other ARDS patients: In the resuscitation phase, controlled fluid replacement combined with vasoactive drugs was given; multiple measures were taken, like lactate and so on, to utilizedto guide fluid resuscitation therapy; diuretics or diuretics in combination with albumin to achieve fluid balance.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha
Description: People received thymosin Alpha subcutaneous injections, twice a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscle relaxant therapy
Description: Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Chinese and Western Medicine Treatment
Description: 1. ventilation;~2. conventional western medicine treatment；~3. Chinese herbal medicine（Determining medication based on syndrome differentiation）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin therapy
Description: 1. Simvastatin: 80mg qd po for not more than 28days;~2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anti-infective treatment
Description: According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Membrane Oxygenation（ECMO）
Description: 1. For severe ARDS patients with refractory hypoxemia within 7 days of onset;~2. (Inspiratory oxygen concentration) ≥ 0.80, tidal volume 6ml/kg (PBW), positive end-expiratory pressure \[PEEP\] ≥ 10 cmH2O;~3. V-V Model.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: stem cell therapy
Description: A single injection of bone marrow stem cells, doses of 1, 5, 10\*106 cells/kg was taken according to the previous clinical studies.